SMMT · Summit Therapeutics Inc.
$17.55
+0.55 (+3.24%)
At close · Sep 11
Going-concern doubt
— flagged Jul 23, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Jul 23, 2026
Market Cap
$14.00B
Shares
797.75M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$17.55
Open$17.20
Day$17.14–17.70
52W close$12.43–26.38
Avg vol 30d5.6M
Short int41.3M · 5.2% float · 6.6d
Short vol59%
Last earningsJul 23, 2026
DataJan 2020–Sep 2026
Filing10-Q · Jul 23
Up next
Next earnings call
Nov 12, 2026
Est · unconfirmed
· in 9 wks
filed Jul 23, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+4.8%
Year over year · more shares
Price change (1Y)
-5.6%
Trailing year
Short interest
5.2%
Latest settlement · 6.6 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Neutral
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 15.8 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+7%
above
Price vs 50-day avg
+21%
above
RSI (14)
67
neutral
MACD trend
Positive
52-week position
37%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+25%
trailing
6-month return
+13%
trailing
YTD return
0%
this year
Relative strength
−5%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $14 › 200d $16 — 200d above 50d
Institutional flow
Accumulating
+9% holders QoQ · +57 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.18% of float · ▲ +10.4% MoM · 6.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
248 holders — near 3-yr high, broad support
Squeeze score
73
high risk · 0–100
Fundamentals
EPS growth
−365%
Y/Y
Free cash flow
$-323.6M
Quant / Vol
risk profile
Volatility
71%
annualized · 1-yr
Max drawdown
−53%
past year
ATR
5.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+7%
Bullish
Price vs 50-day avg
+21%
Bullish
RSI (14)
67
Neutral
MACD trend
Positive
Bullish
52-week position
37%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $14 › 200d $16 — 200d above 50d
Institutional flow
Accumulating
+9% holders QoQ · +57 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.18% of float · ▲ +10.4% MoM · 6.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
248 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $12
Now $18 · 37%
Range high $26
vs 200-day avg +7%
vs 50-day avg +21%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SMMT
this stock
Summit Therapeutics Inc.
|
$14.00B | +0.3% | — | — | 5.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.64B | +13.7% | +46.2% | 30.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.46B | +1.2% | +20.8% | 19.4 | 2.5% |
|
ARGX
Argenx SE
|
$61.22B | +17.1% | — | — | 2.0% |
|
MRNA
Moderna, Inc.
|
$57.48B | +388.2% | +4.3% | — | 9.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SMMT | +2.5% | +25.4% | +13.2% | +28.9% | +0.3% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | +3.6% | +27.1% | -4.7% | +29.2% | -11.7% |
Key facts
CIK
1599298
CUSIP
86627T108
13F (30d)
93 filings
93 filers
Visit website
Investor relations